Topotecan

• CAT Number: I000954
• CAS Number: 123948-87-8
• Molecular Formula: C23H23N3O5
• Molecular Weight: 421.45
• Purity: ≥95%
• Storage: 3 years -20°C powder
• IUPAC Name: (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
• InChI: InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1
• InChIKey: UCFGDBYHRUNTLO-QHCPKHFHSA-N
• SMILES: CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O

Topotecan（Cat No.:I000954）is a topoisomerase I inhibitor with the molecular formula C23H23N3O5, used as a chemotherapeutic agent for treating cancers such as ovarian cancer, small cell lung cancer, and cervical cancer. It works by stabilizing the DNA-topoisomerase I complex, preventing DNA re-ligation during replication, leading to DNA strand breaks and apoptosis in rapidly dividing cells. Topotecan is available as an intravenous formulation and an oral capsule. Common side effects include myelosuppression, nausea, fatigue, and alopecia. It is typically used in patients with advanced or relapsed disease and requires careful dosing and monitoring.

Reference

[1] Semiha Kevser Bali, et al. Biochemistry . 2018 Mar 6;57(9):1542-1551.
[2] Karimnia N, et al. J Exp Clin Cancer Res. 2021 Sep 1;40(1):276.
[3] Wang X, et al. Arthritis Rheumatol. 2021 Aug;73(8):1478-1488.